Opening A Window: Algeta Must Find Xofigo’s Place In The Prostate Cancer Market
Executive Summary
Bayer/Algeta’s Xofigo was cleared for castration-resistant prostate cancer patients with symptomatic bone metastases, but uptake of the radiotherapeutic will require referrals from most providers to a licensed radiation site and the company must find a way for the drug to be used instead of or in sequence with chemo and other prostate cancer therapies.
You may also be interested in...
Endocyte's ABX Deal To Serve As Springboard For Radioligand Pipeline
Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.
Deals Of The Week: Can Endo Succeed By Copying The Valeant Model?
NuPathe and its migraine patch product Zecuity are the latest acquisition by Endo since former Valeant executive Rajiv De Silva moved into the chief executive’s office – will he succeed in bringing his former company’s model to the specialty firm? Plus, Valeant made its own news during the week, while AstraZeneca bought out Bristol’s share of their diabetes joint venture, and more.
Algeta’s Bayer Buyout: Assessing A Rare Case of Partner Acquisition
Few biotechs are acquired by their partners -- only about a half dozen in each of the last two years, making the Bayer acquisition of Algeta an exception to the rule. Like other recent billion-dollar partner acquisitions, expectations for subsequent performance seem high.